FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:200-202 July 17, 1997 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Koh, K. K.

To the Editor: Koh et al. (March 6 issue)¹ report that the administration of conjugated estrogen alone or with progestin reduced plasminogen-activator inhibitor type 1 (PAI-1) levels in postmenopausal women, and the authors speculate that this may contribute to the protective effect of hormone-replacement therapy against coronary artery disease. Whether hormone-replacement therapy increases or decreases the risk of thromboembolic episodes is controversial. Several authors have reported an increased incidence of thromboembolic episodes and blood-coagulation changes, resulting in a hypercoagulable state in patients undergoing hormone-replacement therapy. On the other hand, the improvement in lipid patterns in patients undergoing hormone-replacement therapy may . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.